Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe | Zendy

Hubertus Rosery | Zendy; Walleser | Zendy; Ray | Zendy; Bischoff | Zendy; A. Vergnenègre | Zendy; C. Chouaïd | Zendy; Heigener | Zendy; Javier de Castro | Zendy; Marcello Tiseo | Zendy; Stefan Walzer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

Author(s) -

Hubertus Rosery,

Walleser,

Ray,

Bischoff,

A. Vergnenègre,

C. Chouaïd,

Heigener,

Javier de Castro,

Marcello Tiseo,

Stefan Walzer

Publication year - 2012

Publication title -

clinicoeconomics and outcomes research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.591

H-Index - 27

ISSN - 1178-6981

DOI - 10.2147/ceor.s31794

Subject(s) - erlotinib , medicine , oncology , lung cancer , bioinformatics , erlotinib hydrochloride , cancer research , cancer , epidermal growth factor receptor , biology

First-line maintenance erlotinib in patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and progression-free survival benefits compared with best supportive care plus placebo, irrespective of epidermal growth factor receptor (EGFR) status (SATURN trial). The cost-effectiveness of first-line maintenance erlotinib in the overall SATURN population has been assessed and published recently, but analyses according to EGFR mutation status have not been performed yet, which was the rationale for assessing the cost-effectiveness of first-line maintenance erlotinib specifically in EGFR wild-type metastatic NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research